BioWorld

Nov. 10, 2009

View Archived Issues

Enzon Offloads Specialty Arm to Sigma-Tau for up to $327M

Enzon Pharmaceuticals Inc. has agreed to sell its specialty pharmaceutical business to Italian-owned Sigma-Tau Pharmaceuticals Inc. for $300 million plus up to an additional $27 million based on milestones. (BioWorld Today) Read More

Trius and Alimera Join Growing Roster of Biotech IPO Hopefuls

Read More

Twists and Turns Still Ahead for Health Reform after House Vote

Read More

D-Pharm Taking Stroke Drug into China with $25.5M Deal

Read More

Clinic Roundup

Read More

Other News To Note

Read More

ACAAI Roundup

Read More